DaVita (NYSE:DVA) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of DaVita (NYSE:DVA) from a hold rating to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.

A number of other brokerages also recently issued reports on DVA. Barclays increased their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group boosted their price objective on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday. TD Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and upped their price objective for the stock from $126.00 to $220.00 in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and an average price target of $187.83.

DaVita Stock Performance

NYSE:DVA opened at $198.39 on Thursday. The stock has a 50-day simple moving average of $153.03 and a 200 day simple moving average of $132.70. DaVita has a 52-week low of $101.00 and a 52-week high of $199.27. The company has a market cap of $12.74 billion, a PE ratio of 18.40, a PEG ratio of 0.64 and a beta of 0.84.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts predict that DaVita will post 15.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several large investors have recently modified their holdings of DVA. Root Financial Partners LLC grew its stake in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the period. Caitlin John LLC acquired a new position in DaVita during the 4th quarter worth about $34,000. Sankala Group LLC bought a new stake in shares of DaVita in the 4th quarter valued at about $39,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of DaVita in the second quarter valued at about $43,000. Institutional investors own 90.12% of the company’s stock.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported Q1 results that topped expectations, with adjusted EPS of $2.87 versus consensus near $2.33 and revenue of $3.42 billion above estimates. The company also lifted its 2026 EPS guidance, reinforcing confidence in the earnings outlook. DaVita (DVA) Is Up 27.6% After Boosting 2026 EPS Guidance On Strong Q1 Results
• Positive Sentiment: UBS raised its price target on DaVita to $235 from $190 and kept a Buy rating, signaling further upside potential after the post-earnings rally. UBS Group Issues Positive Forecast for DaVita (NYSE:DVA) Stock Price
• Positive Sentiment: Multiple Zacks articles highlighted DaVita as a Strong Buy value stock and pointed to improving earnings estimate revisions, which can attract momentum and value investors. Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
• Positive Sentiment: Seeking Alpha said DaVita was upgraded to Buy after strong Q1 results, improved volumes, and a favorable valuation profile, supporting the case that the stock can continue to outperform. DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
• Neutral Sentiment: DaVita also announced participation in the BofA Securities 2026 Health Care Conference, which may keep the company in front of investors but is not a direct operating catalyst. DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.